Efficacy of Imatinib According to BCR-ABL Mutation in Patients with CML; Multi-Centered Analytical Study

This is the authors' abstract. We don't add key points for this paper.

Background: Imatinib, a name of assurance in the treatment of CML, not only brings significant prognosis and remission but also improves the quality of life of a patient. The study aimed to evaluate the efficacy of Imatinib in CML patients. Methods: This study was cross-sectional and multi-centered, starting from 2019-2024 from Sylhet, Chittagong, and Rajshahi. In this study, 529 patients were enrolled. Among them, 442 patients were taken, rest of the patients declined as BCR- ABL1 observed copies were <10,000. Sampling was done by convenient technique. Result: The patients' ages ranged from under 20 to over 80 years, with the majority falling between 21-30 years (25.71%) and 31-40 years (23.25%). The majority of the patients were male (57.66%). According to the analytical result, 442 patients (83.55%) tested positive. Among the 442 participants who tested positive for BCR-ABL1 mRNA, 155 patients (35.07%) were in remission. In contrast, 287 patients (64.93%) were not in remission, with an IS ratio greater than 0.1%. Among the 155 patients classified as in remission according to the IS ratio (≤0.1%), all 155 (100.00%) were also in remission according to the transcript percent ratio (≤10%). The sensitivity of the transcript percent ratio in identifying patients in remission was 100.00%, indicating that all patients in remission according to the IS categorization were also identified as in remission by the transcript percent ratio. The specificity was 36.60%, reflecting a lower ability to correctly identify patients not in remission. Conclusion: In the case of specificity, International-scale and large-scale clinical studies with long-term patient outcomes are more recommended.